1. Home
  2. BWAY vs ALLO Comparison

BWAY vs ALLO Comparison

Compare BWAY & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$16.49

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.31

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWAY
ALLO
Founded
2003
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
450.8M
539.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BWAY
ALLO
Price
$16.49
$2.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
15
Target Price
$13.25
$8.35
AVG Volume (30 Days)
144.8K
14.4M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$309.69
N/A
Revenue Next Year
$26.21
$142,416.42
P/E Ratio
$81.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.59
$0.86
52 Week High
$26.63
$4.46

Technical Indicators

Market Signals
Indicator
BWAY
ALLO
Relative Strength Index (RSI) 59.22 47.02
Support Level $14.56 $1.92
Resistance Level $16.63 $2.71
Average True Range (ATR) 0.71 0.35
MACD 0.41 -0.04
Stochastic Oscillator 95.83 17.43

Price Performance

Historical Comparison
BWAY
ALLO

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: